.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A02B_DrugsForPepticUlcerAndGastroOesophagealRefluxDis.A02BA53_FamotidineCombinations.FamotidineCombinations .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A02B_DrugsForPepticUlcerAndGastroOesophagealRefluxDis.A02BA53_FamotidineCombinations.FamotidineCombinations| name: | FamotidineCombinations | |
| ATC code: | A02BA53 | route: | oral |
| compartments: | 1 | |
| dosage: | 20 | mg |
| volume of distribution: | 1.1 | L |
| clearance: | 400 | mL/min |
| other parameters in model implementation | ||
Famotidine is a histamine H2-receptor antagonist used to reduce stomach acid production. It is indicated for the treatment of peptic ulcers, gastroesophageal reflux disease (GERD), and conditions of pathological hypersecretory states such as Zollinger-Ellison syndrome. Famotidine, both alone and in combination with antacids or other components (ATC code A02BA53), is approved for use today to control gastric acid-related disorders.
Estimated pharmacokinetic parameters for healthy adult subjects administered famotidine in fixed-dose combinations, as there are no directly referenced PK studies for ATC code A02BA53. Parameters are based on extrapolation from monotherapy data.